- Granted U.S. FDA Fast Track Designation for ATH434 to treat Multiple System Atrophy (MSA)
- Reported positive topline data from open-label Phase 2 clinical trial of ATH434 i… [+15882 chars]
Visiting original passage: Appendix 4C – Q4 FY25 Quarterly Cash Flow Report
Appendix 4C – Q4 FY25 Quarterly Cash Flow Report
ALTERITY THERAPEUTICS LIMITED •
Highlights Granted U.S. FDA Fast Track Designation for ATH434 to treat Multiple System Atrophy (MSA)Reported positive topline data from open-label Phase...